OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+19.78%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$251M
AUM Growth
+$251M
(+17%)
Cap. Flow
+$11.2M
Cap. Flow
% of AUM
4.47%
Top 10 Holdings %
Top 10 Hldgs %
49.32%
Holding
52
New
15
Increased
11
Reduced
9
Closed
6
Top Buys
| 1 |
AFMD
Affimed
AFMD
|
$7.95M |
| 2 |
Harrow
HROW
|
$4.21M |
| 3 |
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
|
$4.04M |
| 4 |
Axogen
AXGN
|
$3.56M |
| 5 |
FibroGen
FGEN
|
$3.14M |
Top Sells
| 1 |
Agios Pharmaceuticals
AGIO
|
$8.49M |
| 2 |
CMRX
Chimerix, Inc.
CMRX
|
$5.78M |
| 3 |
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
|
$5.22M |
| 4 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$4.39M |
| 5 |
KITE
Kite Pharma, Inc.
KITE
|
$4.38M |
Sector Composition
| 1 | Healthcare | 82.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CMRX
1
DELISTED
Chimerix, Inc.
CMRX
| $20.3M | 8.09% | 440,000 -125,000 | -22% | -$5.78M |
|
|
CEMP
2
DELISTED
Cempra, Inc.
CEMP
| $16.8M | 6.7% | 490,000 -10,000 | -2% | -$344K |
|
3
Travere Therapeutics
TVTX
$1.56B
| $15.2M | 6.07% | 460,000 -40,000 | -8% | -$1.33M |
|
|
AMAG
4
DELISTED
AMAG Pharmaceuticals, Inc.
AMAG
| $13.1M | 5.22% | 190,000 | – | – |
|
|
ARIA
5
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $12.4M | 4.94% | 1,500,000 | – | – |
|
6
Ultragenyx Pharmaceutical
RARE
$2.89B
| $11.3M | 4.48% | 110,000 | – | – |
|
|
7
Harrow
HROW
$1.44B
| $9.8M | 3.9% | 1,205,000 +517,900 | +75% | +$4.21M |
|
8
Supernus Pharmaceuticals
SUPN
$2.53B
| $9.08M | 3.61% | 535,000 | – | – |
|
|
AFMD
9
DELISTED
Affimed
AFMD
| $7.95M | 3.16% | +590,300 | New | +$7.95M |
|
|
CLVS
10
DELISTED
Clovis Oncology, Inc.
CLVS
| $7.91M | 3.15% | 90,000 -50,000 | -36% | -$4.39M |
|
11
Geron
GERN
$893M
| $7.81M | 3.11% | 1,825,000 | – | – |
|
|
12
FibroGen
FGEN
$47.8M
| $7.64M | 3.04% | 325,000 +133,662 | +70% | +$3.14M |
|
13
MiMedx Group
MDXG
$1.05B
| $7.15M | 2.85% | 617,000 +27,000 | +5% | +$313K |
|
14
Neurocrine Biosciences
NBIX
$13.8B
| $6.93M | 2.76% | 145,000 | – | – |
|
15
Codexis
CDXS
$246M
| $6.71M | 2.67% | 1,724,000 | – | – |
|
|
16
Axogen
AXGN
$743M
| $6.66M | 2.65% | 2,120,000 +1,134,100 | +115% | +$3.56M |
|
|
AVDL
17
Avadel Pharmaceuticals
AVDL
$1.43B
| $6.57M | 2.61% | 310,000 +10,000 | +3% | +$212K |
|
|
GNMX
18
DELISTED
Aevi Genomic Medicine, Inc.
GNMX
| $6.44M | 2.56% | 1,050,000 +200,000 | +24% | +$1.23M |
|
|
ISEE
19
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $5.49M | 2.18% | 105,000 | – | – |
|
|
TRIL
20
DELISTED
Trillium Therapeutics Inc.
TRIL
| $5.46M | 2.17% | 250,000 -10,000 | -4% | -$218K |
|
|
ZSPH
21
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
| $4.98M | 1.98% | 95,000 +20,000 | +27% | +$1.05M |
|
|
AMRN
22
Amarin Corp
AMRN
$311M
| $4.32M | 1.72% | 1,754,000 | – | – |
|
|
TVRD
23
Tvardi Therapeutics, Inc. Common Stock
TVRD
$281M
| $4.13M | 1.64% | 340,000 +25,000 | +8% | +$304K |
|
|
EGRX
24
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $4.04M | 1.61% | +50,000 | New | +$4.04M |
|
|
ADMS
25
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $3.93M | 1.56% | 150,000 -105,000 | -41% | -$2.75M |
|